Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | CHIEF FINANCIAL OFFICER | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RAPID MICRO BIOSYSTEMS, INC.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 568,981 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 12,787 · Balance 568,981 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2031-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 23:41 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries B Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · derivative · entry 3 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2031-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:41 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries A Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2027-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:41 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 12,787 | $1.96 | $24,998.59 |
DisclosureSEC source: 0001289733-26-000014 · wk-form4_1780443683.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,981 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 23:52 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 7,480 | $4.32 | $32,299.39 |
DisclosureSEC source: 0001289733-26-000011 · wk-form4_1773359572.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,194 F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units. Read SEC document |
| February 20, 2026 Filed Feb 21, 2026 00:19 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 17,254 | $3.92 | $67,687.44 |
DisclosureSEC source: 0001289733-26-000008 · wk-form4_1771633140.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,674 F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:34 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001380106-26-000015 · wk-form4_1771029276.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Class A Common Stock · 193,000 shares Expires 2036-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2026. Read SEC document |
| February 11, 2026 Filed Feb 14, 2026 00:34 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 97,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-26-000015 · wk-form4_1771029276.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,928 F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2026 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 23:54 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 6,027 | $3.78 | $22,798.33 |
DisclosureSEC source: 0001289733-26-000004 · wk-form4_1770767690.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 483,928 F1 · shares: Represents the automatic sale of stock to cover the associated tax obligations with the vesting of restricted stock units. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 23:18 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 7,690 | $2.39 | $18,379.10 |
DisclosureSEC source: 0001380106-25-000074 · wk-form4_1741735118.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 489,955 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligation. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:59 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 121,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001380106-25-000037 · wk-form4_1740095987.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,000 Underlying: Class A Common Stock · 121,000 shares Expires 2035-02-17 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 18, 2025. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:59 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 160,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-25-000037 · wk-form4_1740095987.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,645 F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 18, 2025 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:02 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 4,621 | $2.68 | $12,384.28 |
DisclosureSEC source: 0001380106-25-000028 · wk-form4_1739494957.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,645 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:12 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 5,891 | $3.10 | $18,262.10 |
DisclosureSEC source: 0001380106-25-000022 · wk-form4_1738977151.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,266 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 21:35 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 10,000 | $0.78 | $7,800.00 |
DisclosureSEC source: 0001380106-24-000179 · wk-form4_1723152949.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,157 F1 · balance_after: Includes 12,754 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 14, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 01:20 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 7,454 | $0.98 | $7,312.37 |
DisclosureSEC source: 0001380106-24-000084 · wk-form4_1710292809.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,403 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:25 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 3,794 | $0.96 | $3,642.24 |
DisclosureSEC source: 0001380106-24-000043 · wk-form4_1707949474.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,857 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:10 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 103,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001380106-24-000033 · wk-form4_1707430245.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Class A Common Stock · 103,000 shares Expires 2034-02-05 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 6, 2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:10 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 51,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-24-000033 · wk-form4_1707430245.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,651 F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 6, 2024 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 11:36 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 10,000 | $0.99 | $9,894.00 |
DisclosureSEC source: 0001380106-23-000157 · wf-form4_169417300562345.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,651 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.920 to $1.020 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 6,739 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on March 14, 2023. Read SEC document |
| March 09, 2023 Filed Mar 14, 2023 01:28 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 198,600 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001289733-23-000002 · wf-form4_167875728496179.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,600 Underlying: Class A Common Stock · 198,600 shares Expires 2033-03-08 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on April 9, 2023. Read SEC document |
| March 09, 2023 Filed Mar 14, 2023 01:28 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 78,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001289733-23-000002 · wf-form4_167875728496179.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,912 F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of March 9, 2023 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 02:39 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Tax withholdingClass A Common Stock | 4,621 | $1.30 | $6,007.30 |
DisclosureSEC source: 0001127602-23-005431 · form4.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,312 F1 · shares: Represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 3,302 shares acquired under the Rapid Micro Biosystems, Inc. employee stock purchase plan on September 14, 2022. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 21:45 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010083 · form4.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,886 Underlying: Class A Common Stock · 10,000 shares Expires 2028-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was originally granted for 223,282 shares and vested and became exercisable as to 25% of the underlying shares on September 12, 2019 and in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 21:45 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | Exercise / conversionClass A Common Stock | 10,000 | $1.00 | $10,000.00 |
DisclosureSEC source: 0001127602-22-010083 · form4.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:41 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.82 | $0.00 |
DisclosureSEC source: 0001127602-22-005159 · form4.xml · derivative · entry 2 WIRTJES SEAN M · CIK 0001289733 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Class A Common Stock · 80,000 shares Expires 2032-02-10 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:41 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005159 · form4.xml · nonDerivative · entry 1 WIRTJES SEAN M · CIK 0001289733 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,631 F1 · shares: Grant of restricted stock units ("RSUs") that vest in three annual installments with 33.4% vesting on the first anniversary of February 11, 2022 (the "grant date") and 33.3% vesting on each of the second and third anniversaries of the grant date provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.